13F-HR filed by Flagship Pioneering, LLC
Flagship Pioneering, LLC filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 7 holding rows worth $1,325,311,872.
- Accession
- 0000950123-24-002510
- Filer
- CIK 1400240
- Filed
- 2024-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2023
A holdings report, 13 entries on the cover page, a total value of $1,325,311,872 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,325,311,872 with VALUE read as dollars as filed, 13F file number 028-17559. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerFlagship Ventures Fund V General Partner LLC 028-18466
- included managerFlagship Ventures Fund IV General Partner LLC 028-17238
- included managerNoubar Afeyan 028-19988
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| MODERNA INC | 60770K107 | COM | 9,666,038 | $961,287,479 | dollars as filed | |
| SANA BIOTECHNOLOGY INC | 799566104 | COM | 25,001,856 | $102,007,573 | dollars as filed | |
| OMEGA THERAPEUTICS INC | 68217N105 | COMMON STOCK | 29,225,579 | $87,968,993 | dollars as filed | |
| FOGHORN THERAPEUTICS INC | 344174107 | COMMON STOCK | 12,674,120 | $81,748,073 | dollars as filed | |
| DENALI THERAPEUTICS INC COM | 24823R105 | Stock | 2,319,968 | $49,786,513 | dollars as filed | |
| SERES THERAPEUTICS INC | 81750R102 | COM | 23,117,045 | $32,434,165 | dollars as filed | |
| SYROS PHARMACEUTICALS INC | 87184Q206 | COM NEW | 1,293,848 | $10,079,076 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-24-002510 | this filing | 2024-02-14 | acceptance time not in the bulk data set |